ESTEVE’S RDI, AGAIN RATED ’EXCELLENT’ BY THE PROFARMA PLAN
The Profarma Plan (Plan for the Promotion of Scientific Research, Development and Technological Innovation in the Pharmaceutical Industry), a joint program of the Ministry of Industry, Energy and Tourism and of the Ministry of Health, Social Services and Equality, has again rated ESTEVEs RDI as 'excellent'
This rating acknowledges the companys commitment to innovation, with an important part of its workforce devoted to top-level research. Over the last year, ESTEVE has invested more than 81 million Euros in R&D.
ESTEVE appears in Group A of the Profarma Plan (2017-2020), which includes companies that conduct significant research activities and have their own center of production or basic or preclinical R&D.
The main purpose of the Profarma Plan is to increase the competitiveness of the pharmaceutical industry in Spain by modernizing the sector, strengthening the activities that provide the highest added value, and fostering research, development and innovation.
ESTEVE ANNOUNCES A RESTRUCTURING OF ITS PHARMACEUTICAL ACTIVITY
Esteve Pharmaceuticals submits a reduction in force (RIF) which will affect 103 jobs in Spainread more
NURSES OFFER CARE AND PREVENTION OF DRY EYE, A CONDITION THAT AFFECTS 60% OF PEOPLE OLDER THAN 45 YEARS
Dry eye care and prevention is a pending issue in the Spanish society and a source of great concern for specific patients, such as those admitted to Intensive Care Units.read more
The longer time...
ONE THIRD OF DIABETIC PATIENTS ARE OLDER THAN 75 YEARS AND THEIR HYPOGLYCEMIA GOES UNDETECTED IN 1 OUT OF 5 CASES
According to experts attending Diabeclass, a meeting organized by ESTEVEread more
at its corporate headquarters titled "Managing elderly patients with
type 2 diabetes".
The priority ...